| Transcription factor interactions: selectors of positive or negative regulation from a single DNA element MI Diamond, JN Miner, SK Yoshinaga, KR Yamamoto Science 249 (4974), 1266-1272, 1990 | 1586 | 1990 |
| Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. E Imai, JN Miner, JA Mitchell, KR Yamamoto, DK Granner Journal of Biological Chemistry 268 (8), 5353-5356, 1993 | 366 | 1993 |
| Regulatory crosstalk at composite response elements JN Miner, KR Yamamoto Trends in biochemical sciences 16, 423-426, 1991 | 320 | 1991 |
| The structural basis of androgen receptor activation: intramolecular and intermolecular amino–carboxy interactions F Schaufele, X Carbonell, M Guerbadot, S Borngraeber, MS Chapman, ... Proceedings of the National Academy of Sciences 102 (28), 9802-9807, 2005 | 271 | 2005 |
| A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects MJ Coghlan, PB Jacobson, B Lane, M Nakane, CW Lin, SW Elmore, ... Molecular endocrinology 17 (5), 860-869, 2003 | 259 | 2003 |
| Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation A Ives, J Nomura, F Martinon, T Roger, D LeRoy, JN Miner, G Simon, ... Nature communications 6 (1), 6555, 2015 | 229 | 2015 |
| The search for safer glucocorticoid receptor ligands J Rosen, JN Miner Endocrine reviews 26 (3), 452-464, 2005 | 228 | 2005 |
| RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer C Iverson, G Larson, C Lai, LT Yeh, C Dadson, P Weingarten, T Appleby, ... Cancer research 69 (17), 6839-6847, 2009 | 212 | 2009 |
| The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. JN Miner, KR Yamamoto Genes & development 6 (12b), 2491-2501, 1992 | 208 | 1992 |
| Urate handling in the human body D Hyndman, S Liu, JN Miner Current rheumatology reports 18 (6), 34, 2016 | 158 | 2016 |
| An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate JN Miner, W Chang, MS Chapman, PD Finn, MH Hong, FJ López, ... Endocrinology 148 (1), 363-373, 2007 | 150 | 2007 |
| Joints in the regulatory lattice: composite regulation by steroid receptor-AP1 complexes JN Miner, MI Diamond, KR Yamamoto Cell Growth Differ 2 (10), 525-530, 1991 | 147 | 1991 |
| Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney JN Miner, PK Tan, D Hyndman, S Liu, C Iverson, P Nanavati, DT Hagerty, ... Arthritis research & therapy 18, 1-10, 2016 | 131 | 2016 |
| Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity MJ Coghlan, PR Kym, SW Elmore, AX Wang, JR Luly, D Wilcox, ... Journal of medicinal chemistry 44 (18), 2879-2885, 2001 | 130 | 2001 |
| Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites D Pearce, W Matsui, JN Miner, KR Yamamoto Journal of Biological Chemistry 273 (46), 30081-30085, 1998 | 129 | 1998 |
| Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia R Fleischmann, B Kerr, LT Yeh, M Suster, Z Shen, E Polvent, V Hingorani, ... Rheumatology 53 (12), 2167-2174, 2014 | 126 | 2014 |
| Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol F Perez-Ruiz, JS Sundy, JN Miner, M Cravets, C Storgard Annals of the rheumatic diseases 75 (6), 1074-1080, 2016 | 115 | 2016 |
| Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout PK Tan, S Liu, E Gunic, JN Miner Scientific reports 7 (1), 665, 2017 | 97 | 2017 |
| Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile JN Miner, B Ardecky, K Benbatoul, K Griffiths, CJ Larson, DE Mais, ... Proceedings of the National Academy of Sciences 104 (49), 19244-19249, 2007 | 96 | 2007 |
| New and improved glucocorticoid receptor ligands JN Miner, MH Hong, A Negro-Vilar Expert opinion on investigational drugs 14 (12), 1527-1545, 2005 | 90 | 2005 |
